1. miR-1297 Promotes Cell Proliferation of Non-Small Cell Lung Cancer Cells: Involving in PTEN/Akt/Skp2 Signaling Pathway.
   Wenjin Bu et al, 2017, DNA Cell Biol CrossRef
2. Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer
   DeokBeom Jung et al, 2018, Sci Rep CrossRef
3. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance
   Li Yang et al, 2018, The American Journal of the Medical Sciences CrossRef
4. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer
   Woong Sub Byun et al, 2018, Biochemical Pharmacology CrossRef
5. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.
   Takeshi Namekawa et al, 2019, Cells CrossRef
6. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis
   Ya-Nan Xue et al, 2019, Prostate CrossRef
7. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist
   D Ruan et al, 2017, Oncogene CrossRef
8. Inhibition of SKP2 Activity Impaired ATM-Mediated DNA Repair and Enhanced Sensitivity of Cisplatin-Resistant Mantle Cell Lymphoma Cells
   Wei Yan et al, 2019, Cancer Biotherapy and Radiopharmaceuticals CrossRef
9. BRAFV600E dictates cell survival via c-Myc-dependent induction of Skp2 in human melanoma
   Lin Feng et al, 2020, Biochemical and Biophysical Research Communications CrossRef
10. Skp2 in the ubiquitin‐proteasome system: A comprehensive review
    Moges Dessale Asmamaw et al, 2020, Med Res Rev CrossRef
11. S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells
    Lu Ding et al, 2018, Int J Oncol CrossRef
12. Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1.
    Akane Kanamori et al, 2020, Oncogene CrossRef
13. Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer
    Yang Yang et al, 2018, Mol Cancer Ther CrossRef
14. Targeting the Hippo Pathway in Prostate Cancer: What’s New?
    Kelly Coffey, 2021, Cancers CrossRef
15. Post-Translational Modifications That Drive Prostate Cancer Progression
    Ivana Samaržija, 2021, Biomolecules CrossRef
16. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade
    Alena Mickova et al, 2021, IJMS CrossRef
17. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
    Hongmei Cui et al, 2021, Front. Pharmacol. CrossRef
18. E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential
    Yuanqi Liu et al, 2021, Front. Pharmacol. CrossRef
19. Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance
    Chune Ren et al, 2021, Cell Death Differ CrossRef
20. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2
    Ting Wu et al, 2022, Cell Biol Toxicol CrossRef
21. Tripartite Motif-Containing Protein 11 Reverses Paclitaxel Resistance in Prostate Cancer Drug-Resistant Cells by Mediating Family with Sequence Similarity 46B Expression
    Hang Guo et al, 2022, Crit Rev Eukaryot Gene Expr CrossRef
22. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies
    Mehrdad Hashemi et al, 2023, Biomedicine & Pharmacotherapy CrossRef
23. LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma
    Yanzhao Jin et al, 2023, Journal of Chemotherapy CrossRef
24. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting
    Silvia Pomella et al, 2023, Nat Commun CrossRef
25. Skp2: A critical molecule for ubiquitination and its role in cancer
    Tianyang Feng et al, 2024, Life Sciences CrossRef
26. Enzyme-independent role of EZH2 in regulating cell cycle progression via the SKP2-KIP/CIP pathway
    Tania Colon et al, 2024, Sci Rep CrossRef
27. The Impact of [C16Pyr][Amp] on the Aggressiveness in Breast and Prostate Cancer Cell Lines.
    Filipa Quintela Vieira et al, 2020, Int J Mol Sci CrossRef
28. Emerging Roles of SKP2 in Cancer Drug Resistance
    Ting Wu et al, 2021, Cells CrossRef